Efficacy and safety of long-acting reversible contraception

Drugs

Volumn 71, Issue 8, 2011, Pages 969-980

  Stoddard, Amy ^a   McNicholas, Colleen ^a   Peipert, Jeffrey F ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Copper; Etonogestrel; Intrauterine contraceptive device; Levonorgestrel.

Indexed keywords

ANTIINFECTIVE AGENT; COPPER INTRAUTERINE DEVICE; ETONOGESTREL; LEVONORGESTREL;

ACNE; AMENORRHEA; APPLICATION SITE BRUISING; APPLICATION SITE REACTION; APPLICATION SITE SORENESS; ARTICLE; BREAST CANCER; CLINICAL TRIAL (TOPIC); CONTRACEPTION; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DEVICE INFECTION; DEVICE REMOVAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RELEASE; DRUG SAFETY; DYSMENORRHEA; ECTOPIC PREGNANCY; ENDOMETRIOSIS; ENDOMETRIUM HYPERPLASIA; FAMILY PLANNING; FEMALE; HEMATOMA; HUMAN; IMPLANT; INTRAUTERINE CONTRACEPTIVE DEVICE; LIVER TUMOR; LUNG EMBOLISM; MENSTRUAL IRREGULARITY; META ANALYSIS (TOPIC); OVULATION; PATIENT COUNSELING; PATIENT SATISFACTION; PELVIC INFLAMMATORY DISEASE; PERFORATION; PREGNANCY; SKIN IRRITATION; SUBDERMAL IMPLANT; UTERINE CERVICITIS; UTERINE TUBE STERILIZATION; VAGINA BLEEDING;

CONTRACEPTION; DRUG IMPLANTS; FEMALE; HUMANS; INTRAUTERINE DEVICES; TREATMENT OUTCOME;

EID: 79958843173     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11591290-000000000-00000     Document Type: Article

References (58)

1. Hatcher RA, Trussell J, Nelson AL, et al., editors. Contraceptive technology. 19th rev. ed.New York: Ardent Media, 2007: 120, 148-9, 759, 874.
2. World Health Organization (WHO). Comparing typical effectiveness of contraceptive methods. Geneva: World Health Organization; 2006.
3. Mosher WD, Jones J. Use of contraception in the United States: 1982-2008. Vital Health Stat 2010; 23 (29): 1-44.
4. Darney P, Patel A, Rosen K, et al. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril 2009; 91 (5): 1646-53.
5. Wenzl R, van Beek A, Schnabel P, et al. Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon. Contraception 1998; 58 (5): 283-8. (Pubitemid 29036549)
6. Kiriwat O, Patanayindee A, Koetsawang S, et al. A 4-year pilot study on the efficacy and safety of Implanon, a single-rod hormonal contraceptive implant, in healthy women in Thailand. Eur J Contracept Reprod Health Care 1998; 3 (2): 85-91. (Pubitemid 128690533)
7. Affandi B, Korver T, Geurts TB, et al. A pilot efficacy study with a single-rod contraceptive implant (Implanon) in 200 Indonesian women treated for < or = 4 years. Contraception, 1999; 59 (3): 167-74 (Pubitemid 29277546)
8. Van den Bosch T, Donders GG, Riphagen I, et al. Ultrasonographic features of the endometrium and the ovaries in women on etonogestrel implant. Ultrasound Obstet Gynecol 2002; 20 (4): 377-80. (Pubitemid 35253736)
9. Mäkäräinen L, van Beek A, Tuomivaara L, et al. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil Steril 1998; 69 (4): 714-21. (Pubitemid 28188469)
10. Funk S,MillerMM,Mishell Jr DR, et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception 2005; 71 (5): 319-26. (Pubitemid 40602307)
11. Ponpuckdee J, Taneepanichskul S. The effects of implanon in the symptomatic treatment of endometriosis. J Med Assoc Thai 2005; 88 Suppl. 2: S7-10.
12. Mansour D, Korver T, Marintcheva-Petrova M, et al. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care 2008; 13 Suppl. 1: 13-28. (Pubitemid 351364453)
13. Chikamata DM, Miller S. Health services at the clinic level and implantable contraceptives for women. Contraception 2002; 65 (1): 97-106. (Pubitemid 34175242)
14. Brache V, Faundes A, Alvarez F, et al. Nonmenstrual adverse events during use of implantable contraceptives for women: data from clinical trials. Contraception 2002; 65 (1): 63-74. (Pubitemid 34175239)
15. Harrison-Woolrych M, Hill R. Unintended pregnancies with the etonogestrel implant (Implanon): a case series from postmarketing experience in Australia. Contraception 2005; 71 (4): 306-8. (Pubitemid 40410081)
16. World Health Organization. Medical eligibility criteria for contraceptive use. 3rd ed.Geneva: S.W.H.O., Reproductive Health and Research, 2004.
17. Levine JP, Sinofsky FE, Christ MF. Assessment of Implanon insertion and removal. Contraception 2008; 78 (5): 409-17.
18. Association of Reproductive Health Professionals. Clinical proceedings: new developments in intrauterine contraception. Washington DC: Association of Reproductive Health Professionals, 2004.
19. Mosher W, Jones J. Use of contraception in the United States: 1982-2008. National Center for Health Statistics. Vital Health Stat 2010; 23 (29): 1-44.
20. Sonfield A. Popularity disparity: attitudes about the IUD in Europe and the United States. Guttmacher Policy Rev 2007; 10: 19-24.
21. Wang D. Contraceptive failure in China. Contraception 2002; 66 (3): 173-8. (Pubitemid 35217867)
22. Harper CC, Blum M, de Bocanegra HT, et al. Challenges in translating evidence to practice: the provision of intrauterine contraception. Obstet Gynecol 2008; 111 (6): 1359-69.
23. Tatum HJ, Schmidt FH, Phillips DM, et al. The Dalkon shield controversy: structural and bacteriologic studies of IUD tails. JAMA 1975; 231 (7): 711-7.
24. Svensson L, Westrom L, Mardh PA. Contraceptives and acute salpingitis. JAMA 1984; 251 (19): 2553-5. (Pubitemid 14149010)
25. Hubacher D, Lara-Ricale R, Taylor DJ, et al. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med 2001; 345 (8): 561-7. (Pubitemid 32772097)
26. Ory HW. Ectopic pregnancy and intrauterine contraceptive devices: new perspectives. The Women's Health Study. Obstet Gynecol 1981; 57 (2): 137-44. (Pubitemid 11183926)
27. Pakarinen P, Toivonen J, Luukkainen T. Therapeutic use of the LNG IUS, and counseling. Semin Reprod Med 2001; 19 (4): 365-72. (Pubitemid 34028424)
28. ACOG Committee Opinion No. 392, December 2007. Intrauterine device and adolescents. Obstet Gynecol 2007; 110 (6): 1493-5.
29. McNaught J. Adolescents and IUCDs: not a contraindication. J Pediatr Adolesc Gynecol 2006; 19 (4): 303-5.
30. Brockmeyer A, Kishen M, Webb A. Experience of IUD/IUS insertions and clinical performance in nulliparous women: a pilot study. Eur J Contracept Reprod Health Care 2008; 13 (3): 248-54.
31. Peipert JF, Zhao Q, Allsworth JE, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol 2011; 117 (5): 1105-13.
32. NilssonCG, HaukkamaaM,Vierola H, et al. Tissue concentrations of levonorgestrel in women using a levonorgestrelreleasing IUD. Clinical Endocrinol 1982; 17: 529-36. (Pubitemid 12006959)
33. Sivin I, Stern J, Coutinho E, et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS. Contraception 1991; 44 (5): 473-80.
34. Bengtson MB, Solberg IC, Aamodt G, et al. Relationships between inflammatory bowel disease and perinatal factors: both maternal and paternal disease are related to preterm birth of offspring. Inflamm Bowel Dis 2010; 16 (5): 847-55.
35. CDC. U S medical eligibility criteria for contraceptive use, 2010 [online]. Available from URL: http://www.cdc.gov/ mmwr/preview/mmwrhtml/ rr59e0528a1.htm [Accessed 2010 Oct 12].
36. Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol 1990; 97 (8): 690-4. (Pubitemid 20263115)
37. Baldaszti E,Wimmer-Puchinger B, Loschke K. Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena): a 3-year follow-up study. Contraception 2003; 67 (2): 87-91. (Pubitemid 36174007)
38. Hidalgo M, Bahamondes L, Perrotti M, et al. Bleeding patterns and clinical performance of the levonorgestrelreleasing intrauterine system (Mirena) up to two years. Contraception 2002; 65 (2): 129-32. (Pubitemid 34258502)
39. Jindabanjerd K, Taneepanichskul S. The use of levonorgestrel- IUD in the treatment of uterine myoma in Thai women. J Med Assoc Thai 2006; 89 Suppl. 4: S147-51.
40. Zapata LB, Whiteman MK, Tepper NK, et al. Intrauterine device use among women with uterine fibroids: a systematic review. Contraception 2010; 82 (1): 41-55.
41. ACOG Practice Bulletin: No. 110. Noncontraceptive uses of hormonal contraceptives. Obstet Gynecol 2010; 115 (1): 206-18.
42. Bahamondes L, Ribeiro-Huguet P, de Andrade KC, et al. Levonorgestrel-releasing intrauterine system (Mirena) as a therapy for endometrial hyperplasia and carcinoma. Acta Obstet Gynecol Scand 2003; 82 (6): 580-2. (Pubitemid 36750713)
43. Mechanism of action, safety and efficacy of intrauterine devices. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 1987; 753: 1-91.
44. Adoni A, Ben Chetrit A. The management of intrauterine devices following uterine perforation. Contraception 1991; 43 (1): 77-81.
45. ACOG Practice Bulletin No. 59, January 2005. Clinical management guidelines for obstetrician-gynecologists: intrauterine device. Obstet Gynecol 2005; 105 (1): 223-32.
46. Walsh T, Grimes D, Frezieres R, et al. Randomised controlled trial of prophylactic antibiotics before insertion of intrauterine devices. IUD Study Group. Lancet 1998; 351 (9108): 1005-8. (Pubitemid 28154375)
47. Teisala K. Removal of an intrauterine device and the treatment of acute pelvic inflammatory disease. Ann Med 1989; 21 (1): 63-5. (Pubitemid 19121854)
48. Soderberg G, Lindgren S. Influence of an intrauterine device on the course of an acute salpingitis. Contraception 1981; 24 (2): 137-43. (Pubitemid 11019194)
49. Penney G, Brechin S, de Souza A, et al. FFPRHC guidance (January 2004). The copper intrauterine device as longterm contraception. J Fam Plann Reprod Health Care 2004; 30 (1): 29-41; quiz 42.
50. Zhou L, Xiao B. Emergency contraception with Multiload Cu-375 SL IUD: a multicenter clinical trial. Contraception, 2001; 64 (2): 107-12.
51. Alvarez F, Brache V, Fernandez E, et al. New insights on the mode of action of intrauterine contraceptive devices in women. Fertil Steril 1988; 49 (5): 768-73.
52. United Nations Development Programme. Long-term reversible contraception: twelve years of experience with the TCu380A and TCu220C. Contraception 1997; 56 (6): 341-52.
53. Sivin I, Stern J, Diaz S, et al. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices. Am J Obstet Gynecol 1992; 166 (4): 1208-13.
54. Vessey MP, Lawless M, McPherson K, et al. Fertility after stopping use of intrauterine contraceptive device [letter]. Br Med J (Clin Res Ed), 1983; 286 (6359): 106. (Pubitemid 13147576)
55. Hubacher D, Grimes DA. Noncontraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynecol Surv 2002; 57 (2): 120-8. (Pubitemid 34132150)
56. Hubacher D, Chen PL, Park S. Side effects from the copper IUD: do they decrease over time? Contraception 2009; 79 (5): 356-62.
57. National Centre for Research Resources [online]. Available from URL: http://www.ncrr.nih.gov [Accessed 2011 Apr 12].
58. National Institutes of Health [online]. Available from URL: http://nihroadmap.nih.gov/clinicalresearch/overview-translational.asp [Accessed 2011 Apr 12]